DHR · Earnings call · 2026Q3T · Full report

Life Sciences End-Market Trends

DANAHER CORP /DE/ · 2026-10-21 · Importance 20 · Surprise 24

Management said Life Sciences end markets continue to improve steadily, with large pharma and biopharma remaining robust and biotech funding beginning to show through in demand. Academic demand remained below historic levels but improved modestly sequentially, while clinical and applied markets, including microelectronics at Pall, continued to show strength. Management also reported early customer demand for AI-driven workflow solutions, first appearing in automation at Beckman Life Sciences, and said it intends to use common standards across instruments to make integration easier for customers.

Key facts

• Danaher’s Life Sciences end markets continued to steadily improve; large pharma and biopharma remained robust, biotech funding was reading through, and academic demand remained below historic levels but improved modestly sequentially.